Sponsor or institution

Clinical trials and research at ImmunityBio, Inc.

• 7Clinical trials
• 4Countries

Newest trials

All recruiting trials (7)

• CD19 t-haNK and N-803 plus rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma

  This treatment tests whether giving lab-grown CD19-directed natural killer cells (t-haNK) together with N-803 and rituximab can help adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior therapy.

  Recruiting at 2 sites Phase 2 ImmunityBio, Inc. · Johannesburg and 1 other locations · NCT07125872

• Anktiva for treating Long COVID symptoms

  This will test whether Anktiva helps adults aged 18–69 who had confirmed COVID-19 and now have persistent or worsened Long COVID symptoms.

  Recruiting Phase 2 ImmunityBio, Inc. · El Segundo, California · NCT07123727

• Anktiva (N-803) for adults with long COVID

  This will test whether Anktiva (N-803), an IL-15 superagonist, is safe and tolerable in adults ages 18–69 who have long COVID.

  Recruiting Phase 2 ImmunityBio, Inc. · San Francisco, California · NCT07108036

• Intravesical recombinant BCG for non‑muscle invasive bladder cancer

  This trial tests a recombinant form of BCG given directly into the bladder to see if it is safe and helps prevent recurrence in adults with BCG‑naïve NMIBC (CIS or Ta/T1).

  Recruiting at 5 sites Phase 1/2 ImmunityBio, Inc. · Chandler, Arizona and 8 other locations · NCT06800963

• Combination treatment for advanced lung cancer

  This study is testing a new combination treatment for advanced lung cancer to see if it works better than the standard single drug treatment.

  Recruiting at 47 sites Phase 3 ImmunityBio, Inc. · Hot Springs, Arkansas and 48 other locations · NCT06745908

• Treatment for recurrent platinum-resistant high-grade ovarian cancer using cell therapy and gemcitabine

  This study is testing a new treatment that combines cell therapy and a chemotherapy drug to see if it can help people with recurrent platinum-resistant high-grade ovarian cancer.

  Recruiting at 2 sites Phase 2 ImmunityBio, Inc. · El Segundo, California and 1 other locations · NCT06710288

• Treatment for patients with relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment for patients with relapsed or hard-to-treat Non-Hodgkin Lymphoma to see if it can help them feel better and improve their condition.

  Recruiting at 2 sites Phase 1 ImmunityBio, Inc. · Newport Beach, California and 1 other locations · NCT05618925

Quick answers

How many clinical trials run by ImmunityBio, Inc. are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in United States (6 trials), Canada (1 trial), United Kingdom (1 trial), South Africa (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 3: 1, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →